Details for Patent: 11,819,480
✉ Email this page to a colleague
Which drugs does patent 11,819,480 protect, and when does it expire?
Patent 11,819,480 protects ORSERDU and is included in one NDA.
This patent has sixty-two patent family members in thirteen countries.
Drugs Protected by US Patent 11,819,480
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stemline Therap | ORSERDU | elacestrant dihydrochloride | TABLET;ORAL | 217639-001 | Jan 27, 2023 | RX | Yes | No | 11,819,480 | ⤷ Subscribe | TREATMENT OF AN ER-POSITIVE BREAST CANCER | ⤷ Subscribe | ||||
| Stemline Therap | ORSERDU | elacestrant dihydrochloride | TABLET;ORAL | 217639-002 | Jan 27, 2023 | RX | Yes | Yes | 11,819,480 | ⤷ Subscribe | TREATMENT OF AN ER-POSITIVE BREAST CANCER | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,819,480
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2016256469 | ⤷ Subscribe | |||
| Australia | 2016256470 | ⤷ Subscribe | |||
| Australia | 2016256471 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
